See more : ZYQC Group Holding Limited (ZYQG) Income Statement Analysis – Financial Results
Complete financial analysis of Pear Therapeutics, Inc. (PEARW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pear Therapeutics, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- GeoVax Labs, Inc. (GOVXW) Income Statement Analysis – Financial Results
- Freund Corporation (6312.T) Income Statement Analysis – Financial Results
- ALX Resources Corp. (ALXEF) Income Statement Analysis – Financial Results
- Nissan Securities Group Co., Ltd. (8705.T) Income Statement Analysis – Financial Results
- Salt Lake Potash Limited (SO4.AX) Income Statement Analysis – Financial Results
Pear Therapeutics, Inc. (PEARW)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://peartherapeutics.com
About Pear Therapeutics, Inc.
Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.69M | 4.21M | 9.38M | 32.56M |
| Cost of Revenue | 8.18M | 5.23M | 1.72M | 998.00K |
| Gross Profit | 4.51M | -1.03M | 7.67M | 31.56M |
| Gross Profit Ratio | 35.54% | -24.36% | 81.69% | 96.94% |
| Research & Development | 48.31M | 37.04M | 28.08M | 35.70M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.55M | 67.62M | 56.23M | 27.47M |
| Other Expenses | 0.00 | -2.05M | -16.82M | 544.00K |
| Operating Expenses | 127.86M | 104.66M | 84.31M | 63.17M |
| Cost & Expenses | 136.04M | 109.89M | 86.03M | 64.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.42M |
| Interest Expense | 3.89M | 0.00 | 2.56M | 0.00 |
| Depreciation & Amortization | -46.05M | -46.74M | 1.43M | -20.10M |
| EBITDA | -169.40M | -152.43M | -75.22M | -51.70M |
| EBITDA Ratio | -1,334.48% | -3,622.27% | -801.52% | -158.79% |
| Operating Income | -123.35M | -105.69M | -76.64M | -31.60M |
| Operating Income Ratio | -971.72% | -2,511.53% | -816.75% | -97.05% |
| Total Other Income/Expenses | 47.86M | 40.54M | -12.17M | 22.27M |
| Income Before Tax | -75.49M | -65.14M | -97.02M | -9.33M |
| Income Before Tax Ratio | -594.70% | -1,548.05% | -1,033.92% | -28.67% |
| Income Tax Expense | -51.75M | -44.85M | 3.56M | -21.73M |
| Net Income | -23.74M | -20.29M | -100.58M | 12.39M |
| Net Income Ratio | -187.02% | -482.27% | -1,071.86% | 38.05% |
| EPS | -0.17 | -0.18 | -0.73 | 0.09 |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| Weighted Avg Shares Out | 138.71M | 113.33M | 137.80M | 137.80M |
| Weighted Avg Shares Out (Dil) | 138.71M | 113.33M | 137.80M | 137.80M |
Source: https://incomestatements.info
Category: Stock Reports